The role of the endocannabinoid system in eating disorders: pharmacological implications
EM Marco, SY Romero-Zerbo, MP Viveros… - Behavioural …, 2012 - journals.lww.com
The endocannabinoid (eCB) system is a widespread intercellular signalling mechanism that
plays a critical role in body homoeostasis. It is located in key points involved in food intake …
plays a critical role in body homoeostasis. It is located in key points involved in food intake …
[HTML][HTML] Role of the endocannabinoid system in the regulation of intestinal homeostasis
H Cuddihey, WK MacNaughton, KA Sharkey - Cellular and molecular …, 2022 - Elsevier
The maintenance of intestinal homeostasis is fundamentally important to health. Intestinal
barrier function and immune regulation are key determinants of intestinal homeostasis and …
barrier function and immune regulation are key determinants of intestinal homeostasis and …
Differential expression of cannabinoid receptors in the human colon: cannabinoids promote epithelial wound healing
K Wright, N Rooney, M Feeney, J Tate, D Robertson… - Gastroenterology, 2005 - Elsevier
Background & Aims: Two G-protein—coupled cannabinoid receptors, termed CB1 and CB2,
have been identified and several mammalian enteric nervous systems express CB1 …
have been identified and several mammalian enteric nervous systems express CB1 …
µ‐opioid receptor, β‐endorphin, and cannabinoid receptor‐2 are increased in the colonic mucosa of irritable bowel syndrome patients
G Dothel, L Chang, W Shih, MR Barbaro… - …, 2019 - Wiley Online Library
Abstract Background and Aims The gut immune, cannabinoid, and opioid systems constitute
an integrated network contributing to visceral sensation and pain modulation. We aimed to …
an integrated network contributing to visceral sensation and pain modulation. We aimed to …
The use of cannabinoids in colitis: a systematic review and meta-analysis
DG Couch, H Maudslay, B Doleman… - Inflammatory bowel …, 2018 - academic.oup.com
Background Clinical trials investigating the use of cannabinoid drugs for the treatment of
intestinal inflammation are anticipated secondary to preclinical literature demonstrating …
intestinal inflammation are anticipated secondary to preclinical literature demonstrating …
The enteric glia and its modulation by the endocannabinoid system, a new target for cannabinoid-based nutraceuticals?
L López-Gómez, A Szymaszkiewicz, M Zielińska… - Molecules, 2022 - mdpi.com
The enteric nervous system (ENS) is a part of the autonomic nervous system that intrinsically
innervates the gastrointestinal (GI) tract. Whereas enteric neurons have been deeply …
innervates the gastrointestinal (GI) tract. Whereas enteric neurons have been deeply …
New approaches and challenges to targeting the endocannabinoid system
V Di Marzo - Nature Reviews Drug Discovery, 2018 - nature.com
The endocannabinoid signalling system was discovered because receptors in this system
are the targets of compounds present in psychotropic preparations of Cannabis sativa. The …
are the targets of compounds present in psychotropic preparations of Cannabis sativa. The …
Emerging role of cannabinoids in gastrointestinal and liver diseases: basic and clinical aspects
AA Izzo, M Camilleri - Gut, 2008 - gut.bmj.com
A multitude of physiological effects and putative pathophysiological roles have been
proposed for the endogenous cannabinoid system in the gastrointestinal tract, liver and …
proposed for the endogenous cannabinoid system in the gastrointestinal tract, liver and …
Cannabinoids and intestinal motility: welcome to CB2 receptors
AA Izzo - British journal of pharmacology, 2004 - Wiley Online Library
Δ9‐Tetrahydrocannabinol (the active ingredient of marijuana), as well as endogenous and
synthetic cannabinoids, exert many biological functions by activating two types of …
synthetic cannabinoids, exert many biological functions by activating two types of …
Olorinab (APD371), a peripherally acting, highly selective, full agonist of the cannabinoid receptor 2, reduces colitis-induced acute and chronic visceral …
Abdominal pain is a key symptom of inflammatory bowel disease and irritable bowel
syndrome, for which there are inadequate therapeutic options. We tested whether olorinab …
syndrome, for which there are inadequate therapeutic options. We tested whether olorinab …